CMAJ/JAMC Special supplement
Supplément spécial

 

Guidelines for red blood cell and plasma transfusion for adults and children

References

  1. Guidelines for Canadian clinical practice guidelines. Ottawa: Canadian Medical Association; 1994.
  2. American Society of Anaesthesiologists Task Force on Blood Component Therapy. Practice guidelines for blood component therapy. Anesthesiology 1996;84:732-47.
  3. Haematology Blood Transfusion Task Force. Guidelines for transfusion for massive blood loss. Clin Lab Haematol 1988;10:265-73.
  4. Silberstein LE, Kruskall MS, Stehling L, Johnston MFM, Rutman RC, Samia C, et al. Strategies for the review of transfusion practices. JAMA 1989;262:1993-7.
  5. Contreras M, Ala FA, Greaves M, Jones J, Levin M, Machin SJM, et al. Guidelines for the use of fresh frozen plasma. British Committee for Standards in Haematology, Working Party of the Blood Transfusion Task Force. Transfus Med 1992;1:57-63.
  6. Fetus and Newborn Committee of the Canadian Paediatric Society. Guidelines for transfusion of erythrocytes to neonates and premature infants. CMAJ 1992;147:1781-95.
  7. Report of a task force to the Conference of Deputy Ministers of Health [cat no H39-3/1980E]. Ottawa: Health Services and Promotion Branch, Department of National Health and Welfare; 1980.
  8. Consent: a guide for Canadian physicians. 3rd ed. Ottawa: Canadian Medical Protective Association; 1996.
  9. Capen K. Physicians and the minefield surrounding informed consent. CMAJ 1996;155:458-60.
  10. Etchells E, Sharpe G, Walsh P, Williams JR, Singer PA. Bioethics for clinicians: 1. Consent. CMAJ 1996;155:177-80.
  11. Widmann F. Informed consent for blood transfusion. Arlington: American Association of Blood Banks; 1989.
  12. Grainger B, Margolese E, Partington E. Guidelines for red blood cell and plasma transfusion: legal and ethical considerations. CMAJ 1997;156:(11 suppl).
  13. Etchells E, Sharpe G, Burgess M, Singer PA. Bioethics for clinicians: 2. Disclosure. CMAJ 1996;155:387-94.
  14. Krever H. Interim report of the Commission of Inquiry on the Blood System in Canada. Ottawa: Ministry of Supply and Services Canada; 1995.
  15. Eisenstaedt RS, Glanz K, Smith DG, Derstine T. Informed consent for blood transfusion: a regional hospital survey. Transfusion 1993;33:558-61.
  16. Etchells E, Sharpe G, Elliott C, Singer PA. Bioethics for clinicians: 3. Capacity. CMAJ 1996;155:657-64.
  17. Clinical guide to transfusion. 3rd ed. Ottawa: Canadian Red Cross Society; 1993.
  18. Priebe HJ. Hemodilution and oxygenation. Int Anesthesiol Clin 1981;19:237-55.
  19. Allen JB, Allen FB. The minimum acceptable level of hemoglobin. Int Anesthesiol Clin 1981;19:1-21.
  20. Tuman KJ. Tissue oxygen delivery: the physiology of anemia. Anesthesiol Clin North Am 1990;9:451-69.
  21. Robertie PG, Gravlee GP. Safe limits of isovolemic hemodilution and recommendations for erythrocyte transfusion. Int Anesthesiol Clin 1990;28:197-204.
  22. Wilkerson DK, Rosen AL, Gould SA, Sehgal LR, Sehgal HL, Moss GS. Oxygen extraction ratio: a valid indicator of myocardial metabolism in anemia. J Surg Res 1987;42:629-34.
  23. Levy PS, Chavez RP, Crystal GJ, et al. Oxygen extraction ratio: a valid indicator of transfusion need in limited coronary reserve? J Trauma 1992;32:769-47.
  24. Levy PS, Kim SJ, Eckel PK, et al. Limit to cardiac compensation during acute isovolemic haemodilution: influence of coronary stenosis. Am J Physiol 1993;265:H340-9.
  25. Schwartz JP, Ludkowski MJ, Segil LJ, Miletich DJ, Law WR, Gould SA. The influence of coronary stenosis on transfusion need. Surg Forum 1993;44:226-8.
  26. Moroff G, Dende D. Characterization of biochemical changes occurring during storage of red cells: comparative studies with CPD and CPDA-1 anticoagulant-preservative solutions. Transfusion 1983;23:484-9.
  27. Messmer K. Hemodilution-possibilities and safety aspects. Acta Anaesthesiol Scand 1988;32:49-53.
  28. Messmer K, Lewis DH, Sunder-Plassmann L, Klovekorn WP, Mendler N, Holper K. Acute normovolemic hemodilution. Changes of central hemodynamics and microcirculatory flow in skeletal muscle. Eur Surg Res 1972;4:55-70.
  29. Duruble M, Martin JL, Duvelleroy M. Effects theoriques, experimentaux et cliniques des variations de l'hematocrite au cours de l'hemodilution. Ann Anesthesiol Fr 1979;9:805-14.
  30. LeMerre C, Dauzat M, Poupard P, Targhetta R, et al. Pulmonary gas exchange is reduced during normovolaemic haemodilution in healthy human subjects. Can J Anaesth 1996;43:672-7.
  31. Shah DM, Gottlieb ME, Rahm RL, et al. Failure of red blood cell transfusion to increase oxygen transport or mixed venous PO2 in injured patients. J Trauma 1982;22:741-6.
  32. Gore DC, DeMaria EJ, Reines HD. Elevations in red blood cell mass reduce cardiac index without altering the oxygen consumption in severely burned patients. Surg Forum 1992;43:721-3.
  33. Babineau TJ, Dzik WH, Borlase BC, Baxter JK, Bistrian D, Benotti PN. Reevaluation of current transfusion practices in patients in surgical intensive care units. Am J Surg 1992;164:22-5.
  34. Hebert PC, Wells GA, Marshall JC, et al. Transfusion requirements in critical care: a pilot study. JAMA 1995;273:1439-44.
  35. Viele MK, Weiskopf RB. What can we learn about the need for transfusion from patients who refuse blood? The experience with Jehovah's Witnessess. Transfusion 1994;43:396-401.
  36. Carson JL, Duff A, Poses JA, et al. Effect of anaemia and cardiovascular disease on surgical mortality and morbidity. Lancet 1996;348:1055-60.
  37. Smith JJ, Kampine JP. Physiology of exercise and the effect of aging. In: Smith JJ, Kampine JP, editors. Circulatory physiology: the essentials. Baltimore: Williams & Wilkins; 1984:219-46.
  38. Vara-Thorbeck R, Guerrero-Fernandez Marcote JA. Hemodynamic response of elderly patients undergoing major surgery under moderate normovolemic hemodilution. Eur Surg Res 1985;17:372-6.
  39. Spahn DR, Zollinger A, Schlumpf RB, et al. Hemodilution tolerance in elderly patients without known cardiac disease. Anesth Analg 1996;82:681-6.
  40. Spahn DR, Schmid ER, Seifert B, Pasch T. Hemodilution tolerance in patients with coronary artery disease who are receiving chronic ß-adrenergic blocker therapy. Anesth Analg 1996;82:687-94.
  41. Rao TLK, Montoya A. Cardiovascular, electrocardiographic and respiratory changes following acute anaemia with volume replacement in patients with coronary artery disease. Anaesthesiol Rev 1985;12:49-54.
  42. Nelson AH, Fleischer LA, Rosenbaum SH. Relationship between postoperative anemia and cardic morbidity in high-risk vascular patients in the intensive care unit. Crit Care Med 1993;21:860-6.
  43. Committee on Trauma. Advanced trauma life support program for physicians. Chicago: American College of Surgeons; 1993.
  44. Messmer K, Sunder-Plassmann L, Jesch F, Gornandt L, Sinagowitz E, Kessler M. Oxygen supply to the tissues during limited normovolemic hemodilution. Res Exp Med 1973;159:152-66.
  45. Spahn DR, Leone BJ, Reves JG, Pasch T. Cardiovascular and coronary physiology of acute isovolemic hemodilution: A review of non-oxygen carrying and oxygen-carrying solutions. Anesth Analg 1994;78:1000-21.
  46. Consensus Conference (National Institute of Health). Perioperative red blood cell transfusion. JAMA 1988;260:2700-3.
  47. Zauder HL. Preoperative hemoglobin requirement. Anesthesiol Clin N Am 1990;8:471-80.
  48. Elwood P, et al. Symptoms and circulating hemoglobin level. J Chronic Dis 1969;21:615.
  49. Canadian Erythropoietin Study Group. Association between recombinant human erythropoietin and quality of life and excercise capacity of patients receiving hemodialysis. BMJ 1990;300:573-8.
  50. Linman J. Physiologic and pathophysiologic effects of anemia. N Engl J Med 1968;279:812.
  51. Card R, Brain M. The "anemia" of childhood: evidence for a physiologic response to hyperphosphatemia. N Engl J Med 1973;228:388-92.
  52. Holzer B, Egger M, Teuscher T, et al. Childhood anemia in Africa: to transfuse or not transfuse? Acta Trop 1993;55:47-51.
  53. Lackritz E, Campbell C, Ruebush II T, et al. Effect of blood tranfusion on survival among children in a Kenyan hospital. Lancet 1992;340:524-8.
  54. Henling C, Carmichael M, Keats A, Cooley D. Cardiac operation for congenital heart disease in children of Jehovah's Witnesses. J Thorac Cardiovasc Surg 1985;89:914-20.
  55. Kawaguchi A, Bergsland J, Subramanian S. Total bloodless open heart surgery in the pediatric age group. Circulation 1984;70:1-30.
  56. Guay J, Hume H, Gauthier M, Tremblay P. Choc hemorragique. In: Urgences et soins intensifs pediatriques. Montreal: Les Presses de l'Université de Montréal; 1994.
  57. Toy PT, Strauss R, Stehling L, Sears R, Price TH, Rossi EC, et al. Predeposited autologous blood for elective surgery: a national multicenter study. N Engl J Med 1987;316:517-20.
  58. Pinkerton PH. Two-years' experience with a Canadian hospital-based autologous blood donor programme. Transfus Med 1994;4:231-6.
  59. Heiss MM, Mempel W, Jauch KW, Delanoff C, Mayer G, Mempel M, et al. Beneficial effect of autologous blood transfusion on infectious complications after colorectal cancer surgery. Lancet 1993;342:1328-33.
  60. Busch ORC, Hop WCJ, Hoynck van Papendrecht MAW, Marquet RL, Jeekel J. Blood transfusions and prognosis in colorectal cancer. N Engl J Med 1993;328:1372-6.
  61. Richards C, Kolins J, Trindale CD. Autologous transfusion-transmitted Yersinia enterocolitica [letter]. JAMA 1996;268:1541-2.
  62. Sire JM, Michelet C, Mesnard R, et al. Septic shock due to Yersinia enterocolitica after autologous transfusion [letter]. Clin Infect Dis 1993;17:954-5.
  63. Duncan KL, Ransley J, Elterman M. Transfusion-transmitted Serratia liquifaciens from an autologous blood unit [letter]. Transfusion 1994;34:738-9.
  64. Haditsch M, Binder L, Gabriel C, et al. Yersinia enterocolitica septicemia in autologous blood transfusion. Transfusion 1994;34:907-9.
  65. Goldman M, Rémy-Prince S, Trépanier A, Décary F. Autologous donation error rates in Canada. Transfusion In press 1997
  66. Britton JD, Eastlund DT, Dziuban SW, Foster ED, Mcllduff JB, Canavan TE, et al. Predonated autologous blood use in elective cardiac surgery. Ann Thorac Surg 1989;47:529-32.
  67. Popvosky MA, Whitaker B, Arnold NL. Severe outcomes of allogeneic and autologous blood donation: frequency and characterization. Transfusion 1995;35:734-7.
  68. Tretiak R, Laupacis A, Rivere M, McKerracher K, Souetre E, Canadian Cost of Transfusion Study Group. Cost of allogeneic and autologous blood transfusion in Canada. CMAJ 1996;154:1501-8.
  69. Birkmeyer JD, Goodnough LT, AuBuchon JP, Noordsu PG, Littenberg B. The cost-effectiveness of preoperative autologous blood donation for total hip and knee replacement. Transfusion 1993;33:544-51.
  70. Etchason J, Petz L, Keeler E, Calhoun L, Kleinman SH, Snider C, et al. The cost effectiveness of preoperative autologous blood donations. N Engl J Med 1995;332:719-24.
  71. Bowden R, Sayers MH. The risk of transmitting cytomegalovirus by FFP. Transfusion 1990;8:762-3.
  72. Consensus Development Panel (United States National Institutes of Health). Fresh-frozen plasma: indication and risks. JAMA 1985;253:551-3.
  73. College of American Pathologists. Practice parameter for the use of fresh-frozen plasma, cryoprecipitate, and platelets: fresh-frozen plasma, cryoprecipitate, and platelets administration practice guidelines. JAMA 1994;10:777-8.
  74. Voak D, Cann R, Finney RD, Fraser ID, Mitchell R, Murphy MF, et al. Guidelines for administration of blood products: transfusion of infants and neonates. British Committee for Standards in Haematology Blood Transfusion Task Force. Transfus Med 1994;1:63-9.
  75. Association of Hemophilia Clinic Directors of Canada. Hemophilia and von Willebrand's disease: 1. Diagnosis, comprehensive care and assessment. CMAJ 1995;153:19-25.
  76. Waytes A, Rosen F, Frank M. Treatment of hereditary angioedema with a vapor-heated C1 inhibitor concentrate. N Engl J Med 1996;334:1630-4.
  77. Makris M, Phillips W, Greaves M, Kitchen S, Rosendaal F, Preston F. Emergency oral anticoagulant reversal: the necessity for prothrombin complex concentrates. Br J Haematol 1996;93:6.
  78. British Committee for Standards in Haematology. Guidelines on oral anticoagulation: second edition. J Clin Pathol 1990;43:177-83.
  79. Gazzard B, Henderson I, Williams R. The use of fresh frozen plasma or a concentrate of factor IX as replacement therapy before liver biopsy. Gut 1975;16:621-5.
  80. Mannucci PM, Franchi F, Dioguardi N. Correction of abnormal coagulation in chronic liver disease by combined use of fresh frozen plasma and prothrombin complex concentrates. Lancet 1976;2:542-5.
  81. McVay PA, Toy PT. Lack of increased bleeding after paracenthesis and thoracentesis in patients with mild coagulation abnormalities. Transfusion 1991;31:164-71.
  82. Ewe K. Bleeding after liver biopsy does not correlate with indices of peripheral coagulation. Dig Dis Sci 1981;26:388-93.
  83. McVay PA, Toy PT. Lack of increased bleeding after liver biopsy in patients with mild hemostatic abnormalities. Am J Clin Pathol 1990;94:747-53.
  84. Friedman EW, Sussman II. Safety of invasive procedures in patients with the coagulopathy of liver diseases. Clin Lab Haematol 1989;11:199-204.
  85. Kovacs MJ, Wong A, MacKinnon K, Weir K, Keeney M, Boyle E, Cruikshank M. Assessment of the validity of the INR system for patients with liver impairment. Thromb Haemost 1994;71:727-30.
  86. Mount MJ, King EG. Severe acute disseminated intravascular coagulation: a reappraisal of its pathophysiology, clinical significance and therapy based on 47 patients. Am J Clin Med 1979;67:557.
  87. Czer LSC, Shoemaker WC. Optimal hematocrit value in critically ill postoperative patients. Surg Gynecol Obstet 1978;147:363-8.
  88. Rutledge R, Sheldon GF, Collins ML. Massive transfusion. Crit Care Clin 1986;2:791-805.
  89. Ham JM. Transfusion reactions. In: Condon RE, DeCosse JJ, editors. Surgical care: a physiologic approach to clinical management. Philadelphia: Lea & Febiger; 1980:178-86.
  90. Reed RL, Ciavarella D, Heimbach DM, et al. Prophylactic platelet administration during massive transfusion. Ann Surg 1988;203:40-8.
  91. Murray DJ, Pennell BJ, Weinstein SL, Olson DJ. Packed red cells in acute blood loss: dilutional coagulopathy as a cause of surgical bleeding. Anesth Analg 1995;80:336-42.
  92. Murray DJ, Olson J, Strauss R, Tinker JH. Coagulation changes during packed red cell replacement of major blood loss. Anesthesiology 1988;69:839-45.
  93. Ciavarella D, Reed RL, Counts RB, Baron L, Pavlin EG, Heimbach E, et al. Clotting factor level and the risk of diffuse microvascular bleeding in the massively transfused patient. Br J Haematol 1987;67:365-8.
  94. Mannucci PM, Federici AB, Sirchia G. Hemostatis testing during massive blood replacement: a study of 172 cases. Vox Sang 1982;42:113-23.
  95. Woodman R, Harker L. Bleeding complications associated with cardiopulomanary bypass. Blood 1990;76:1680-97.
  96. Harker L, Malpass T, Branson H, Hessel EI, Slichter S. Mechanism of abnormal bleeding in patients undergoing cardiopulmonary bypass: acquired transient platelet dysfunction associated with selective a-granule release. Blood 1980;56:824-34.
  97. Teufelsbauer H, Proidl S, Havel M, Vukovich T. Early activation of hemostasis during cardiopulmonary bypass: evidence for thrombin mediated hyperfibrinolysis. Thromb Haemost 1992;68:250-2.
  98. Orchard M, Goodchild C, Prentice C, Davies J, Benoit S, Creighton-Kemsford L, et al. Aprotinin reduces cardiopulmonary bypass-induced blood loss and inhibits fibrinolysis without influencing platelets. Br J Haematol 1993;85:533-41.
  99. Boisclair M, Lane D, Philippou H, Sheikh S, Hunt B. Thrombin production, inactivation and expression during open heart surgery measured by assays for activation fragments including a new ELISA for prothrombin fragment F1+2. Thromb Haemost 1993;70:253-8.
  100. Dietrich W, Spannagl M, Jochum M, Wendt P, Schramm W, Barankay A, et al. Influence of high-dose aprotinin treatment on blood loss and coagulation patterns in patients undergoing myocardial revasculatization. Anesthesiology 1990;73:1119-26.
  101. Royston D, Bidstrup B, Taylor K, Sapsford R. Effect of aprotinin on need for blood transfusion after repeat open-heart surgery. Lancet 1987;2:1289-91.
  102. Bailey C, Wielogorski A. Randomized placebo controlled double blind study of two low dose aprotinin regimes in cardiac surgery. Br Heart J 1994;71:349-53.
  103. DelRossi A, Cernaianu A, Botros S, Lemole G, Moore R. Prophylactic treatment of postperfusion bleeding using EACA. Chest 1989;96:27-30.
  104. Harrow J, Hlavecek J, Strong M, Collier W, Brodsky, I, Goldman S, et al. Prophylactic tranexamic acid decreases bleeding after cardiac operations. J Thorac Cardiovasc Surg 1990;99:70-4.
  105. Angelini G, Cooper G, Lamarra M, Bryan A. Unorthodox use of aprotinin to control life-threatening bleeding after cardiopulmonary bypass. Lancet 1990;335:799-800.
  106. Gelb A, Roth R, Levin J, London M, Noall R, Hauck W, et al. Changes in blood coagulation during and following cardiopulmonary bypass, lack of correlation with clinical bleeding. Am J Clin Pathol 1996;106:87-99.
  107. Milam J, Austin S, Martin R, Keats A, Cooley D. Alteration of coagulation and selected clinical chemistry parameters in patients undergoing open-heart surgery without transfusions. Am J Clin Pathol 1981;76:155-62.
  108. Chandler W, Fitch J, Wall M, Verrier E, Cochran R, Soltow L, et al. Individual variations in the fibrinolytic response during and after cardiopulmonary bypass. Thromb Haemost 1995;74:1293-7.
  109. Martinowitz U, Goor D, Ramot B, Mohr R. Is transfusion of fresh plasma after cardiac operations indicated? J Thorac Cardiovasc Surg 1990;100:92-8.
  110. Vander Salm T, Ansell J, Okike O, Marsicano T, Lew R, Stephenson W, et al. The role of epsilon-aminocaproic acid in reducing bleeding after cardiac operation: a double-blind randomized study. J Thorac Cardiovasc Surg 1988;95:538-40.
  111. Byrnes JJ, Khurana M. Treatment of thrombotic thrombocytopenic purpura with plasma. N Engl J Med 1977;297:1386-9.
  112. Rock GA, Shumak KH, Buskard NA, Blanchette VS, Kelton JG, Nair RC, et al. Comparison of plasma exchange with plasma infusion in the treatment of thrombotic thrombocytopenic purpura. Canadian Apheresis Study Group. N Engl J Med 1991;325:393-7.
  113. Henon P. Traitement du purpura thrombotique thrombopénique. Résultats d'une étude clinique multicentrique randomisée. Presse Méd 1991;20:1761-7.
  114. Moake JL, Rudy C, Troll J, Weinstein M, Colannino N, Azocar J, et al. Unusually large plasma factor VIII: von Willebrand factor multimers in chronic relapsing thrombotic thrombocytopenic purpura. N Eng J Med 1982;307:1432-5.
  115. Moake JL, Byrnes J, Troll J, et al. Effects of fresh-frozen plasma and its cryosupernatant fraction on von Willebrand factor multimeric forms in chronic relapsing thrombotic thrombocytopenic purpura. Blood 1985;65:1232-6.
  116. Byrnes JJ, Moake JL, Klug P, Periman P. Effectiveness of the cryosupernatant fraction of plasma in the treatment of refractory thrombotic thrombocytopenic purpura. Am J Hematol 1990;34:169-74.
  117. Rock GA, Shumak KH, Sutton D, Buskard NA, Nair RC, Members of the Canadian Apheresis Group. Cryosupernatant as replacement fluid for plasmapheresis in thrombotic thrombocytopenic purpura. Br J Haematol 1996;94:383-6.
  118. Andrew M, Schmidt B. Hemorrhagic and thrombotic complications in children. Chapter 51. In: Colman R, Hirsh J, Marder V, Salzman E, editors. Hemostasis and thrombosis: basic principles and clinical practice. 3rd ed. Philadelphia: JB Lippincott Co; 1994:989-1022.
  119. Loirat C, Sonsino E, Hinglais N, Jais JP, Landais P, Fermanian J. Treatment of the childhood hemolytic uraemic syndrome with plasma: a multicentre randomized controlled trial. Pediatr Nephrol 1988;2:279-85.
  120. Ogborn MR, Crocker Jf, Barnard DR. Plasma therapy for severe hemolytic-uremic syndrome in children in Atlantic Canada. CMAJ 1990;143:1323-6.
  121. Linden JV, Paul B, Dressler KP. A report of 104 transfusion errors in New York State. Transfusion 1992;32:601-6.
  122. Popvosky MA. Transfusion reactions. Bethesda (MD): AABB Press; 1996.
  123. Sloop GD, Friedberg RC. Complications of blood transfusion: how to recognize and respond to noninfectious reactions. Postgrad Med 1995;98:159-72.
  124. Capon SM, Sacher RA. Hemolytic transfusion reactions: a review of mechanisms, sequelae, and management. J Intensive Care Med 1989;4:100-11.
  125. Klein HG. Allogeneic transfusion risks in the surgical patient. Am J Surg 1995;170:21S-26S.
  126. Huh YO, Lichtiger B. Transfusion reactions in patients with cancer. Am J Clin Pathol 1987;87:253-7.
  127. Redman M, Regan F, Contreras M. A prospective study of the incidence of red cell allo-immunisation following transfusion. Vox Sang 1996;71:216-20.
  128. Ramsey G. The pathophysiology and organ-specific consequences of severe transfusion reactions. New Horizons 1994;2:575-81.
  129. Heddle N, Klama L, Singer J, Richards C, Fedak P, Walker J, et al. The role of plasma from platelet concentrates in transfusion reactions. N Engl J Med 1994;331:625-8.
  130. Alter HJ. The cloning and clinical implications of HGV and HGBV-C. N Engl J Med 1996;334:1536-7.
  131. Goldfinger D. Clinical and serological aspects of transfusion reactions: a technical workshop. Arlington (VA): American Association of Blood Banks; 1982.
  132. Weiden P. Graft-v-host disease following blood transfusions. Arch Intern Med 1984;144:1557-8.
  133. Cunningham CC, Lind SE. Apparent response of refractory post-transfusion purpura to splenectomy. Am J Hematol 1989;30:112-3.
  134. Puig N, Sayas MJ, Montoro JA, Villalba JV, Pla A. Post-transfusion purpura as the main manifestation of a trilineal transfusion reaction, responsive to steroids: flow-cytometric investigation of granulocyte and platelet antibodies. Ann Hematol 1991;62:232-4.
  135. Nijjar T, Bonacosa I, Israels L. Severe acute thrombocytopenia following infusion of plasma contining anti-PIA1. Am J Hematol 1987;25:219-21.
  136. Warkentin T, Smith J, Hayward C, Ali A, Kelton J. Thrombocytopenia caused by passive transfusion of anti-glycoprotein Ia/IIa alloantibody (anti-HPA-5b). Blood 1992;79:2480-4.
  137. Harrigan C, Lucus CE, Ledgerwood AM, Walz DA, Mammen EF. Serial changes in primary hemostasis after massive transfusion. Surgery 1985;98:836-43.
  138. Rudolph R, Boyd CR. Massive transfusion: complications and their management. South Med J 1990;83:1065-70.
  139. Phillips TF, Souler G, Wilson RF. Outcome of massive transfusion exceeding two blood volumes in trauma and emergency surgery. J Trauma 1987;27:903-10.
  140. Luna GK, Maier RV, Pavlin EG. Incidence and effect of hypothermia in seriously injured patients. J Trauma 1987;27:1014-18.
  141. Sazama K. Reports of 355 transfusion-associated deaths: 1976 through 1985. Transfusion 1990;30:583-90.
  142. Dzik S, Blajchman M, Blumberg N, Kirkley S, Heal J, Wood K. Current research on the immunodulatory effect of allogeneic blood transfusion. Vox Sang 1996;70:187-94.
  143. Jensen L, Kissmeyer-Nielsen P, Wolff B, Qvist N. Randomized comparison of leucocyte-depleted versus buffy-coat-poor blood transfusion and complications after colorectal surgery. Lancet 1996;348:841-5.
  144. Remis R, Delage G, Palmer RWH. Risk of HIV infection from blood transfusion in Montreal, Quebec. CMAJ In press 1997.
  145. Schreiber GB, Busch MP, Kleinman SH, Korelitz JJ. The risk of transfusion-transmitted viral infections. N Engl J Med 1996;334:1685-90.
  146. Holland PV. Viral infections and the blood supply. N Engl J Med 1996;334:1734-5.
  147. Causes of death, 1994. Ottawa: Statistics Canada; 1996. Cat no 84-208-XPB.
  148. Laudan L. The book of risks. New York: John Wiley and Sons; 1994.
  149. Natof H. Outpatient anesthesia: no double standard. Survey reports on 1,100,000 anesthetics given in ambulatory care centres. Anesthesia Patient Safety Foundation Newsletter 1987;2:8.
  150. Gallo D, Yeh E, Moores E, Hanson C. Comparison of four enzyme immunoassays for detection of human T-cell lymphotropic virus type 2 antibodies. J Clin Microbiol 1996;34:213-5.
  151. Lackritz EM, Satten GA, Aberle-Grasse J, et al. Estimated risk of transmission of the human immunodeficiency virus by screened blood in the United States. N Engl J Med 1995;333:1721-5.
  152. Dodd RY. Transfusion-transmitted hepatitis virus infection. Hematol Oncol Clin North Am 1995;9:137-54.
  153. Anonymous. Public Health Service inter-agency guidelines for screening donors of blood, plasma, organs, tissues, and semen for evidence of hepatitis B and hepatitis C. MMWR 1991;40(RR-4):1.
  154. Preiksaitis JK. Indications for the use of cytomegalovirus-seronegative blood products. Transfus Med Rev 1991;1:1-17.
  155. Bowden R, Slichter S, Sayers MH, et al. A comparison of filtered leukocyte-reduced and cytomegalovirus (CMV) seronegative blood products for the prevention of transfusion-associated CMV infection after marrow transplant. Blood 1995;86:3598-603.
  156. Lee P, Chang M, Hwu W, Kao C, Lee C. Transfusion acquired cytomegalovirus infection in children in a hyperendemic area. J Med Virol 1992;36:49-53.
  157. Kao J, Chen P, Lai M, Chen D. GBV-C/HGV infection and aplastic anaemia. Lancet 1996;348:1032-3.
  158. Heringlake S, Osterkamp S, Trautwein C, et al. Association between fulminant hepatic failure and a strain of GBV virus C. Lancet 1996;348:1626-9.
  159. 1994 red book: report of the Committee on Infectious Diseases. 23th ed. Elk Grove Village (IL): American Academy of Pediatrics; 1994.
  160. Bacterial contamination of blood components. (Bull 96-6). Elk Grove (IL): American Association of Blood Banks; 1996.
  161. Kishnan L, Brecher ME. Transfusion-transmitted bacterial infection. Hematol Oncol Clin North Am 1995;9:167-85.
  162. Dodd RY. Infectious complications of blood transfusion. Hematol Oncol Ann 1994;2:280-7.
  163. MacKnight C, Rockwood K. Bovine spongiform encephalopathy and Creutzfeldt-Jakob disease: implications for physicians. CMAJ 1996;155:529-36.
  164. Esmonde T, Will R, Slattery J, Knight R, et al. Creutzfeldt-Jacob disease and blood transfusion. Lancet 1993;341:205-7.
  165. Schonberger L. Creutzfeldt-Jacob disease and blood safety [abstract]. Presented at American Society of Hematology, Orlando (FL), Dec. 6, 1996.
  166. Stehling L, Zauder HL. Acute normovolemic hemodilution. Transfusion 1991;31:857-68.
  167. Weiskopf RB. Mathematical analysis of isovolemic hemodilution indicates that it can decrease the need for allogeneic blood transfusion. Transfusion 1995;35:37-41.
  168. Goodnough LT, Grishaber JE, Monk TG, Catalona WJ. Acute preoperative hemodilution in patients undergoing radical prostatectomy; a case study analysis of efficacy. Anesth Analg 1994;78:932-7.
  169. Feldman JM, Roth JV, Bjoraker DG. Maximum blood savings by acute normovolemic hemodilution. Anesth Analg 1995;80:108-13.
  170. Brecher ME, Rosenfeld M. Mathematical and computer modeling of acute normovolemic hemodilution. Transfusion 1994;34:176-9.
  171. Fremes SE, Wong BI, Lee E, et al. Meta-analysis of prophylactic drug treatment in the prevention of postoperative bleeding. Ann Thorac Surg 1994;58:1580-8.
  172. Goodnough LT, Price TH, Friedman K, Johnston MFM, Ciavarella D, Khan N, et al. A phase III trial of recombinant human erythropoietin therapy in nonanemic orthopedic patients subjected to aggresive removal of blood for autologous use: dose, response, toxicity, and efficacy. Transfusion 1994;34:66-71.
  173. Price TH, Goodnough LT, Vogler W, Sacher RA, Hellman R, Johnston MFM, et al. The effect of recombinant human erythropoietin on the efficacy of autologous blood donation in patients with low hematocrits: a multicentre, randomized, double-blind, controlled trial. Transfusion 1996;36:29-36.
  174. Canadian Orthopaedic Perioperative Study Group. Effectiveness of perioperative recombinant human erythropoietin in elective hip replacement. Lancet 1993;341:1227-32.
  175. Goodnough LT. The safety of recombinant human erythropoietin therapy in autologous blood donors. J Lab Clin Med 1994;124:17-8.
  176. Hess J. Blood substitutes. Semin Hematol 1996;33:369-78.
  177. AuBuchon JP. Minimizing donor exposure in hemotherapy. Arch Pathol Lab Med 1994;118:380-91.
  178. AuBuchon JP, Popvosky MA. The safety of preoperative autologous blood donation in the nonhospital setting. Transfusion 1991;31:513-7.
  179. Hillyer CD, Hart KK, Lackey DAI, Lin LS, Bryan JA. Comparable safety of blood collection in high-risk autologous donor versus non-high-risk autologous and directed donors in a hospital setting. Am J Clin Pathol 1994;102:275-7.
Previous:  Addendum
[Table of Contents]
| CMAJ June 1, 1997 (vol 156, no 11) / JAMC le 1er juin 1997 (vol 156, no 11) |
CPG Infobase / Infobanque des GPC